{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:51Z","timestamp":1789011591330,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12955-018-1013-9","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T15:05:37Z","timestamp":1537542337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States"],"prefix":"10.1186","volume":"16","author":[{"given":"Eytan M.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Galebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl Q.","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"issue":"9","key":"1013_CR1","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B Deschler","year":"2006","unstructured":"Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099\u2013107.","journal-title":"Cancer"},{"key":"1013_CR2","unstructured":"National Cancer Institute (NCI): Surveillance E, and End Results Program. Cancer Stat Facts: Acute Myeloid Leukemia (AML). Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html . Accessed 16 Feb 2016."},{"key":"1013_CR3","unstructured":"American Cancer Society. What Are the Key Statistics About Acute Myeloid Leukemia? Available from: https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html . Accessed 17 Mar 2017."},{"issue":"1","key":"1013_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0305-7372(03)00142-7","volume":"30","author":"A Redaelli","year":"2004","unstructured":"Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev. 2004;30(1):103\u201317.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1013_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3324\/haematol.2010.036715","volume":"96","author":"EN Oliva","year":"2011","unstructured":"Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;96(5):696\u2013702.","journal-title":"Haematologica"},{"key":"1013_CR6","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines: Acute Myeloid Leukemia. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf . Accessed 13 Mar 2017."},{"key":"1013_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/asheducation.V2012.1.43.3798183","volume":"2012","author":"J Szer","year":"2012","unstructured":"Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:43\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"1013_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1989.tb04253.x","volume":"71","author":"HD Preisler","year":"1989","unstructured":"Preisler HD, Anderson K, Rai K, Cuttner J, Yates J, DuPre E, et al. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol. 1989;71(2):189\u201394.","journal-title":"Br J Haematol"},{"issue":"1","key":"1013_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","volume":"114","author":"J Pidala","year":"2009","unstructured":"Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7\u201319.","journal-title":"Blood"},{"issue":"20","key":"1013_CR10","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1001\/jama.2016.16786","volume":"316","author":"A El-Jawahri","year":"2016","unstructured":"El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2016;316(20):2094\u2013103.","journal-title":"JAMA"},{"key":"1013_CR11","unstructured":"National Institute for Health and Clinical Excellence- Decision Support Unit (NICE-DSU). NICE DSU techinical support document 11: Alternatives to EQ-5D for generating health state utility values. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK425861\/pdf\/Bookshelf_NBK425861.pdf . Accessed 6 Mar 2018."},{"issue":"5","key":"1013_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/annonc\/mdr559","volume":"23","author":"P Blinman","year":"2012","unstructured":"Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol. 2012;23(5):1104\u201310.","journal-title":"Ann Oncol"},{"key":"1013_CR13","unstructured":"National Institute for Health and Care Excellence (NICE). Process and methods guides: Guide to the methods of technology appraisal. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword . Accessed 14 June 2017."},{"key":"1013_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CEOR.S153286","volume":"10","author":"A Forsythe","year":"2018","unstructured":"Forsythe A, Brandt PS, Dolph M, Patel S, Rabe APJ, Tremblay G. Systematic review of health state utility values for acute myeloid leukemia. Clinicoecon Outcomes Res. 2018;10:83\u201392.","journal-title":"Clinicoecon Outcomes Res"},{"key":"1013_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4020-5753-3","volume-title":"SpringerLink (online service). Using discrete choice experiments to value health and health care","author":"M Ryan","year":"2007","unstructured":"Ryan M, Amaya-Amaya M, Gerard K. SpringerLink (online service). Using discrete choice experiments to value health and health care. Dordrecht: Springer; 2007. Available from: https:\/\/doi.org\/10.1007\/978-1-4020-5753-3"},{"issue":"16","key":"1013_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"2013","author":"FRLE Johnson","year":"2013","unstructured":"Johnson FRLE, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;2013(16):3\u201313.","journal-title":"Value Health"},{"issue":"4","key":"1013_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"key":"1013_CR18","unstructured":"Kuhfeld W. Marketing research methods in SAS. Experimental design, choice, conjoint, and graphical techniques. Available from: http:\/\/support.sas.com\/techsup\/technote\/mr2010.pdf . Accessed 13 Mar 2017."},{"issue":"8","key":"1013_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40273-015-0292-9","volume":"33","author":"F Xie","year":"2015","unstructured":"Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, et al. A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE). PharmacoEconomics. 2015;33(8):867\u201377.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"1013_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jhealeco.2011.11.004","volume":"31","author":"N Bansback","year":"2012","unstructured":"Bansback N, Brazier J, Tsuchiya A, Anis A. Using a discrete choice experiment to estimate health state utility values. J Health Econ. 2012;31(1):306\u201318.","journal-title":"J Health Econ"},{"key":"1013_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.socscimed.2014.05.026","volume":"114","author":"N Bansback","year":"2014","unstructured":"Bansback N, Hole AR, Mulhern B, Tsuchiya A. Testing a discrete choice experiment including duration to value health states for large descriptive systems: addressing design and sampling issues. Soc Sci Med. 2014;114:38\u201348.","journal-title":"Soc Sci Med"},{"issue":"6","key":"1013_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hec.2953","volume":"23","author":"R Viney","year":"2014","unstructured":"Viney R, Norman R, Brazier J, Cronin P, King MT, Ratcliffe J, et al. An Australian discrete choice experiment to value eq-5d health states. Health Econ. 2014;23(6):729\u201342.","journal-title":"Health Econ"},{"issue":"9","key":"1013_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/hec.3066","volume":"23","author":"Y Gu","year":"2014","unstructured":"Gu Y, Norman R, Viney R. Estimating health state utility values from discrete choice experiments--a QALY space model approach. Health Econ. 2014;23(9):1098\u2013114.","journal-title":"Health Econ"},{"key":"1013_CR24","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"B Orme","year":"2006","unstructured":"Orme B. Getting started with conjoint analysis: strategies for product design and pricing research. Madison, WI: Research Publishers LLC; 2006."},{"key":"1013_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2288-12-15","volume":"12","author":"J Cheng","year":"2012","unstructured":"Cheng J, Pullenayegum E, Marshall DA, Marshall JK, Thabane L. An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening. BMC Med Res Methodol. 2012;12:15.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1013_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health"},{"issue":"1","key":"1013_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.0006-341X.2001.00120.x","volume":"57","author":"W Pan","year":"2001","unstructured":"Pan W. Akaike's information criterion in generalized estimating equations. Biometrics. 2001;57(1):120\u20135.","journal-title":"Biometrics"},{"key":"1013_CR28","unstructured":"United States Census Bureau. United States 2010 Census. Available from: https:\/\/www.census.gov\/programs-surveys\/decennial-census\/decade.2010.html . Accessed 27 Mar 2017."},{"issue":"9","key":"1013_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17474086.2016.1211006","volume":"9","author":"SA Buckley","year":"2016","unstructured":"Buckley SA, Lee SJ, Walter RB. Measuring quality of life in acute myeloid leukemia: limitations and future directions. Expert Rev Hematol. 2016;9(9):821\u20133.","journal-title":"Expert Rev Hematol"},{"key":"1013_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12955-014-0156-6","volume":"12","author":"J Wu","year":"2014","unstructured":"Wu J, Han Y, Zhao FL, Zhou J, Chen Z, Sun H. Validation and comparison of EuroQoL-5 dimension (EQ-5D) and short Form-6 dimension (SF-6D) among stable angina patients. Health Qual Life Outcomes. 2014;12:156.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1013_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s11136-010-9639-z","volume":"19","author":"O Cunillera","year":"2010","unstructured":"Cunillera O, Tresserras R, Rajmil L, Vilagut G, Brugulat P, Herdman M, et al. Discriminative capacity of the EQ-5D, SF-6D, and SF-12 as measures of health status in population health survey. Qual Life Res. 2010;19(6):853\u201364.","journal-title":"Qual Life Res"},{"issue":"4","key":"1013_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1524-4733.2006.00108.x","volume":"9","author":"M Bharmal","year":"2006","unstructured":"Bharmal M, Thomas J 3rd. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health. 2006;9(4):262\u201371.","journal-title":"Value Health"},{"key":"1013_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12955-015-0377-3","volume":"13","author":"M Aristides","year":"2015","unstructured":"Aristides M, Barlev A, Barber B, Gijsen M, Quinn C. Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom. Health Qual Life Outcomes. 2015;13:181.","journal-title":"Health Qual Life Outcomes"},{"key":"1013_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"KM Beusterien","year":"2010","unstructured":"Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O'Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:50.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1013_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","volume":"13","author":"SM Szabo","year":"2010","unstructured":"Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health. 2010;13(1):103\u201311.","journal-title":"Value Health"},{"issue":"9865","key":"1013_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","volume":"381","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484\u201395.","journal-title":"Lancet"},{"issue":"1","key":"1013_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","volume":"127","author":"EM Stein","year":"2016","unstructured":"Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood. 2016;127(1):71\u20138.","journal-title":"Blood"},{"key":"1013_CR38","unstructured":"Ryan C, Bauman K. Educational attainment in the United States: 2015. Available from: https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2016\/demo\/p20-578.pdf . Accessed 27 Mar 2017."},{"issue":"7436","key":"1013_CR39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","volume":"328","author":"M Ryan","year":"2004","unstructured":"Ryan M. Discrete choice experiments in health care. BMJ. 2004;328(7436):360\u20131.","journal-title":"BMJ"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-018-1013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12955-018-1013-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-018-1013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T11:40:47Z","timestamp":1571917247000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-018-1013-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1186\/s12955-018-1013-9","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"2 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved under the exemption category from the New England Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.S. has received consultancy fees and\/or research funding from Novartis, Agios Pharmaceuticals, Celgene Corporation, Pfizer, GSK, Seattle Genetics, and Constellation Pharma. G.B., S.B., and G.J.J. are employees of Novartis Pharmaceuticals Corporation and own stock\/stock options. M.Y, A.G, W.G, P.G., and C.X. are employees of Analysis Group, Inc., which has received consultancy fees from Novartis Pharmaceuticals Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"193"}}